Oncology: Molecular Characterization (Audio-Digest Foundation Oncology Continuing Medical Education (CME).) by Audio Digest see more by Audio Digest

Closer Look Salesrank: 775788 Released: 2012-06-11 Released: 2012-06-11 Lowest New Price: Click Here  Pages: 18 Format: Kindle Edition Also Shop International: (Not all items available internationally)          Oncology: Molecular Characterization (Audio-Digest Foundation Oncology Continuing Medical Education (CME).) Editorial Review: Purpose: Audio-Digest Foundation CME/CE activities are designed to provide its learners – physicians and other healthcare professionals – with continuing education that will help identify clinical problems in their practice settings, provide content to help to solve those problems, and increase their application of knowledge to practice. Audio-Digest Oncology is specifically designed to provide the participant with up-to-date and accurate information on areas of competency as identified by the ABIM Medical Oncology MOC Examination Blueprint and ASCO's Core Curriculum Outline. Topics include, but are not limited to, the following: The 37 cancer types and sites Treatment regimens and methods, including chemotherapy, radiation therapy, hormonal therapies, and biological response modifiers Other treatment-related issues, including oncological emergencies, paraneoplastic syndrome, bone marrow transplantation, local therapy of metastatic cancers, and management of malignant effusions Complications, including infections and other complications of treatment; effects of disease and treatment on the patient, including psychosocial and psychological issues Supportive care, including pain management, hematopoietic growth factors, transfusion therapy,nutritional support, end-of-life care, etc. Procedures, including chemotherapy administrations, tumor assessment, bone marrow aspiration, biopsy and interpretation Geriatric oncology The goal of this program is to improve the management of lung cancer and multiple myeloma. After hearing and assimilating this program, the clinician will be better able to: 1: Prescribe appropriate treatment for patients with non-small cell lung cancer (NSCLC). 2: Evaluate the evidence for the use of biomarker profiling in selecting therapies for patients with NSCLC. 3: Use genetic risk profiling to determine the most effective therapies for patients with multiple myeloma (MM). 4: Identify candidates for autologous or allogenic stem cell transplantation among patients with MM. 5: Recognize the role of novel therapies in the treatment of MM. Related Categories: >> >>Books >>Subjects >>Health, Family & Lifestyle >>Medical & Healthcare Practitioners >>Internal Medicine >>Diseases & Disorders >>Oncology >>General AAS